Stockreport

Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia

Synlogic, Inc.  (SYBX) 
Last synlogic, inc. earnings: 3/12 04:19 pm Check Earnings Report
PDF – SYNB1020 well tolerated in Phase 1b/2a study, but did not lower blood ammonia in patients with cirrhosis –– Company will focus resources on advancement of SYNB1618, SY [Read more]